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The Saccharomyces cerevisiae protein Ure2 functions as a regulator of nitrogen metabolism and as a glutathione-dependent peroxidase. Ure2
also has the characteristics of a prion, in that it can undergo a heritable conformational change to an aggregated state; the prion form of Ure2 loses
the regulatory function, but the enzymatic function appears to be maintained. A number of factors are found to affect the prion properties of Ure2,
including mutation and expression levels of molecular chaperones, and the effect of these factors on structure and stability are being investigated.
The relationship between structure, function and folding for the yeast prion Ure2 are discussed.
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The structure and function of a protein are intimately related.
A large number of disease states have been attributed to protein
misfolding or aggregation. Disease may arise from loss of
normal function or, as suggested in the case of amyloid
aggregates, by gain of toxic function. A subset of amyloid
diseases arises apparently due to infection with a misfolded
protein, or prion [1]. The prion diseases include Creutzfeldt–
Jacob disease (CJD) in humans, and bovine spongiform
encephalopathy (BSE) and scrapie in animals. The BSE
epidemic in the UK [2], and subsequent appearance of a new
variant of the human disease [3], has highlighted the importance
of research in this area. However, despite more than a decade of
intensive research, the molecular mechanism of prion propaga-
tion, and even the normal function of the mammalian prion
protein, PrP, remain mysterious. While progress has been made
towards showing that infectivity of the mammalian prionAbbreviations: BSA, bovine serum albumin; CDNB, 1-chloro-2,4-dinitro-
benzene; GdmCl, guanidine hydrochloride; GPx, glutathione peroxidase; GSH,
glutathione; GSSG, oxidized glutathione; GST, glutathione transferase; CHP,
cumene hydroperoxide; t-BH, tert-butyl hydroperoxide; ThT, Thioflavin T
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controversy continues [6].
Wickner proposed that the genetic behaviour of the
Saccharomyces cerevisiae non-Mendelian element [URE3]
could be explained if it were a prion of the Ure2 protein [7].
Since then much evidence has accumulated to support this
proposal. To date, there are at least two other proteins in S.
cerevisiae that also satisfy the biochemical and genetic criteria
to be classed as prions [8,9], namely Sup35/[PSI+] [10–12]
and Rnq1/[RNQ/PIN+] [13,14], and a number of other
candidate prions have been identified by searching for prion
domain-like sequence regions [15]. In addition, [Het-s] has
been identified as a prion of the filamentous fungus Podospora
anserina [16,17]. The relative simplicity and tractability of
yeast and other fungal systems has allowed convincing proof
of the protein-only hypothesis for Het-s [18], Sup35 [19,20]
and Ure2 [21].
These various proteins are related via the prion concept;
however, comparison of their structural and functional proper-
ties shows limited similarity (see Fig. 1). The Het-s protein
lacks the Asn/Gln-rich region characteristic of the yeast prions
identified so far, although it is similarly divided into a globular
functional region and a flexible prion domain [22]. The
relationship between domain structure and function for the
PrP protein is more complex. The PrP protein has a flexible N-
Fig. 1. Comparison of structural and functional properties of prion proteins: Ure2 [27,29,58], Sup35 [114,115], Rnq1 [13], Het-s [22] and PrP [23,24,116,117]. The
functional regions are as indicated. Repetitive regions correspond to Asn/Gln-rich regions, except for PrP, in which residues 60 to 91 include four copies of an
octapeptide repeat sequence Pro–His–Gly–Gly–Gly–Trp–Gly–Gln (PHGGGWGQ) [25,118].
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involved in copper binding [25], but this flexible region only
partially overlaps with the segment that is required for
infectivity (see Fig. 1). As further prion proteins are identified
and characterized, it may become clear whether the presence of
a flexible tail in the native state is a necessary feature in order to
undergo a switch to a prion structure. The fact that prions exist
in yeast provides an ideal environment for detailed genetic
analysis of factors affecting prion maintenance; this coupled
with biochemical characterization should contribute to under-
standing of the molecular mechanism of amyloid formation and
prion propagation.
2. Structure and function of Ure2
2.1. Introduction
Ure2 is a 354-amino acid protein consisting of a relatively
flexible and protease-sensitive N-terminal region, and a
globular C-terminal region [26–28]. The C-terminal region
of Ure2 shows structural similarity to glutathione transferasesFig. 2. Primary sequence of Ure2 and design of N-terminal deletion mutants. Repeti
region has homology to the glutathione transferase protein family [29].(GSTs) and is necessary and sufficient for its regulatory
function: Ure2 interacts with the transcription factor Gln3
allowing control of nitrogen catabolite repression, blocking the
uptake of poor nitrogen sources in the presence of a good
nitrogen source [29,30]. The N-terminal region of Ure2 is
required for its prion properties in vivo [31] and to form
amyloid-like filaments in vitro [32–34]. However, deletion of
the N-terminal region has no detectable effect on the stability
or folding of the protein in vitro [27,33,35,36]. The N-terminal
approximately 90 residues of Ure2 are rich in asparagine and
glutamine (see Fig. 2). Glutamine-repeats are associated with a
number of neurodegenerative diseases, including Huntington's
disease [37]. The ability of glutamine (or asparagine) repeats
to aggregate by forming a hydrogen bonded β-sheet structure
is thought to lead to disease [38–40], either by incorporation
of vital cellular proteins into the aggregates [41,42], or by
direct toxicity of the aggregates themselves [43]. The Ure2
system is therefore a useful model not only to investigate the
prion concept, but also to understand the properties of Gln/
Asn-repeat proteins and hence the molecular basis of the
related diseases.tive regions are indicated by diagonal stripes or bold type [27]. The C-terminal
Fig. 3. Comparison of crystal structures for the C-terminal globular domain of
Ure2 (PDB code 1k0d; blue) with glutathione bound (purple) and the β-class
glutathione transferase for E. coli (PDB code 1a0f; yellow) with glutathione
sulfonic acid bound (white). The figure was produced using the program VMD
[119].
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The glutathione transferases are a multifunctional family of
enzymes, broadly distributed in nature, that play a critical role in
cellular detoxification [44–49]. GSTs have the general function
of conjugating glutathione (GSH) to electrophilic substances to
reduce their toxicity. As a consequence, GSTs are involved in
development of resistance towards drugs, insecticides and
herbicides, and have a protective role against a range of
diseases, including cancer. GSTs are dimeric proteins, with a
relatively conserved N-terminal thioredoxin-like domain and a
more variable C-domain. GST structures have been divided into
a series of classes, including alpha, mu, pi, sigma and theta, on
the basis of differences in structure and activity. The theta class,
thought to be the progenitor of the other classes, is the most
diverse [45] and further subdivisions have been suggested, such
as beta for bacterial GSTs [46]. GST activity is typically tested
using the ‘universal’ GST substrate 1-chloro-2,4-dinitrobenzene
(CDNB). However, a number of GSTs identified by structural
criteria have failed to show activity towards CDNB, particularly
among theta class and bacterial enzymes, which are found to
catalyze a diverse range of specific reactions [44]. Some GSTs
have been shown to have overlapping functions with other
glutathione binding enzymes, such as glutathione peroxidases
(GPxs) and glutaredoxins [47–49]. These enzyme families
share the GSH binding thioredoxin domain, but are otherwise
structurally and mechanistically dissimilar. In particular, GPxs
contain a selenocysteine, which reacts covalently with GSH,
generally via a ping-pong enzyme reaction mechanism [50]. In
contrast, GSTs use a conserved tyrosine, serine or cysteine
residue to interact with the thiol group of GSH, thus increasing
the reactivity of GSH, typically via a sequential mechanism
[51–53]. In S. cerevisiae, the two GSTs that have been
identified show activity towards CDNB, but do not possess
peroxidase activity [54]. On the other hand, the two
glutaredoxins are active towards both CDNB and hydroper-
oxides [55] and the three phospholipid hydroperoxide glutathi-
one peroxidases show activity towards both lipid and non-lipid
hydroperoxides [56]. The versatility of the glutathione binding
enzymes, and their tendency to show overlapping functions,
may contribute significantly to the ability of the host organism
to adapt to change. Utilizing this potential, the GST fold has
been used as a scaffold to design proteins with altered activity
and specificity [49,57].
The Ure2 protein was identified as belonging to the theta
class of glutathione transferases on the basis of sequence
similarity [29,45]. Subsequent availability of crystal structures
of the truncated C-domain of Ure2 in both the apo form [28,58]
and with glutathione bound [59] has confirmed its classification
as a theta (or beta) class GST (see Fig. 3). However, Ure2 does
not show a detectable level of GST activity with typical
substrates, such as CDNB [27,29,54,60]. Recent studies have
found that deletion of the URE2 gene increases the sensitivity of
S. cerevisiae cells to heavy metals and cellular oxidants, such as
hydrogen peroxide [60–62]; and a Ure2 homologue from
Aspergillus nidulans, while lacking the nitrogen metabolite
repression activity of Ure2, also contributes to heavy metal andxenobiotic resistance [63]. Peroxidase activity of Ure2 towards
oxidant substrates including hydrogen peroxide as well as
typical organic hydroperoxides, such as cumene hydroperoxide
and tert-butyl hydroperoxide (t-BH), has been demonstrated for
the purified protein in vitro, confirming the function of Ure2 as
a glutathione dependent peroxidase [64].
A number of questions remain regarding the relationship
between Ure2 structure and its enzyme function. Interestingly,
the residue suggested to be involved in activation of GSH on the
basis of the crystal structure [59] is an Asn residue, N124;
whereas in other known GSTs, the crucial catalytic residue is a
Ser, Tyr, or Cys. Another interesting question regards GPx
activity, which is observed in GSTs from a variety of organisms
to exist as an adjunct of GST activity, while in the case of Ure2,
GPx activity is present but typical GST activity is lacking.
Mutagenesis studies will be required to pin-point the residues
essential for substrate activation and binding. Further studies are
also needed to understand the mechanistic and structural basis
of the relationship between GST and GPx activity, for GST-like
proteins in general and Ure2 in particular.
2.3. Relationship between enzymatic, regulatory and prion
functions of Ure2
Strains of S. cerevisiae containing the [URE3] prion were
found to show normal sensitivity towards hydroperoxides [60].
Further, it was found that formation of amyloid-like fibrils had
negligible effect on the level of GPx activity detected for
purified protein in vitro [64]. Taken together, this indicates that
Ure2 GPx activity is maintained upon structural conversion to
the aggregated prion form. This is in contrast to the loss of
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the basis of detection of the [URE3] prion phenotype [7,65].
This suggests that the loss of regulatory function is attributable
to a steric blocking mechanism, rather than to conformational
changes per se. This also raises potential questions about the
relative importance of the enzymatic and regulatory functions
in evolutionary terms. Deletion of the URE2 gene is non-
lethal, implying that, at least in the lab environment, both
enzymatic and regulatory functions are dispensable. It remains
uncertain whether the [URE3] prion ever crops up in the wild
[66] and the ability of Ure2 protein homologues to switch to
the [URE3] prion form is conserved in some yeast species but
not others [67,68]. There nevertheless remains the possibility
that the additional epigenetic variability provided by the prion-
switch provides an advantage in surviving changes in
environment. The loss of the nitrogen regulatory function of
Ure2 in strains containing the [URE3] prion, while GPx
activity is maintained, is probably due to the relative sizes of
the ligands involved in these reactions, and not any reflection
of the relative importance of the respective activities. The
purpose and evolutionary implications of fungal prions are
discussed elsewhere [8,9,66,67,68].Fig. 4. (A) Mutations in the N-terminal prion domain of Ure2 that affect prion pr
observed; −, not observed (or very low rate of occurrence); ND, not determined; NA
background in an initially [URE3] prion strain [70,120]. bInactivation of the Ure2 prot
expressed in vivo in a WT background [70]. cInduction of the [URE3] prion when t
dAbility to propagate the prion state when the gene is expressed in vivo in a null (ure2Δ
is expressed in vivo in a ure2Δ background [69]. (This is not applicable to N-termin
heritable loss of Ure2 function, which is the signature of the [URE3] prion.) (B) Effe
solution in phosphate buffer, pH 7.5 [27]. Note that all constructs can be solubilized
fusion proteins have been observed in bacterial cell extracts [109]. bRelative rate of
time; +, longer lag time; −, no increase in ThT binding observed) [34]. cRelative ThT
AFM after incubation in phosphate buffer (+++, long fibrils; ++, short fibrils; +, rod
changes in fibril thickness (height) under all conditions and that no differences in fi3. Factors affecting [URE3] prion formation
3.1. Mutation
A number of mutations in the URE2 gene have been shown
to affect the prion behaviour (see Figs. 4 and 5). The N-terminal
prion domain (PrD) of Ure2 was initially defined as residues 1–
65, on the basis that when this region was deleted, the [URE3]
prion state could not be induced and conversely, overexpression
of the 1–65 fragment resulted in a 6000-fold increase in the rate
of prion induction [31]. In fact, smaller deletions, such as 2–20,
are able to ablate prion inducing ability [31] and overexpression
of larger fragments, such as 1–80, result in even higher rates of
induction [69]. Sequence comparison of Ure2 homologs in
different yeast species indicates that in general, the PrDs are
divergent in protein sequence, but the region 10–40 is relatively
conserved across different yeast species, and within Saccharo-
myces species, the conserved region extends to residues 1–43
[70]. Interestingly, the conserved region correlates with the
ability of N-terminal fragments to interfere with prion
propagation (“curing”) in [URE3] strains [70]. Further, the
conserved region is involved in nucleation of amyloid-likeoperties in vivo. Experimental details are given in the references indicated. +,
, not applicable. aCuring of the prion state when the gene is expressed in a WT
ein (but not necessarily induction of a stable prion [URE3] state) when the gene is
he gene is expressed in a WT background in an initially non-prion strain [31].
) background [69]. eSpontaneous generation of the [URE3] prion when the gene
al fragments that lack the Ure2 functional region because they cannot show the
ct of N-terminal mutations in vitro. aSolubility in E. coli cell extracts or in pure
using Tris–HCl buffer, pH 8.4 [27], and that amyloid-like fibrils of Ure2 PrD
nucleation of amyloid-like structure, assayed by ThT binding (+++, shorter lag
binding in plateau phase [34]. dRelative lengths of fibrillar structures detected by
s; −, no fibrils). Note that WT and mutant fibrils show the same time-dependent
bril length were observed in Tris–HCl buffer [34].
Fig. 5. Crystal structure of the C-terminal globular domain of Ure2 (PDB code 1g6w) showing the sites of mutations that affect prion function, as indicated. The
mutations are the deletion of residues of 151–158, deletion of residues 221–227, deletion of the C-terminal 7 residues [72]; and the mutants K127E or V271E when
combined with point mutations in the N-terminus (see text) [73]. The figure was produced using the program VMD [119].
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amyloid-specific dye Thioflavin T in vitro [34]. On the other
hand, a series of Ure2 variants produced by scrambling the
sequence within the Ure2 PrD were found to behave as prions in
vivo and form amyloid fibrils in vitro [71], suggesting that the
prion properties of Ure2 principally reflect the amino acid
composition of the prion domain, rather than the specific
primary sequence. Therefore the reason for the conservation of
sequence in the Ure2 PrD between different yeast species
remains an interesting question.
Mutations affecting the prion properties of Ure2 are not
restricted to the N-terminal PrD. A number of deletions in the C-
terminal region have been found to increase or decrease the
prion-inducing propensity of Ure2 [72]. These include deletion
of residues 221–227, which decreases prion induction, and the
deletions 151–158 or 348–354, which increase the rate of prion
induction. Interestingly, while deletion of the prion domain (1–
65) alone removes prion inducing ability, this deletion in
combination with the deletion of the regions 151–158 and 348–
354 produces a fragment that can once again induce prion
formation. In addition to these deletions, screening of a
mutagenised library identified a mutant of Ure2 containing a
series of point mutations (2 in the N-terminal domain, 7 in the
C-domain) that results in a 1000-fold increase in the rate of
prion induction when the mutant is overexpressed in a WT
background [73]. In fact, 50% of this increase in induction rate
could be attributed to a pair of mutants in the N-terminus (S10L
and R17C) combined with a single mutation in the C-terminus
(K127E). While this triple mutant is non-functional in nitrogen
regulation, a mutation pair (S10L/V271E) was identified that is
functional, but is still 10× more efficient than WT at inducingthe [URE3] prion phenotype [73]. The results of these
mutagenesis studies imply not only the involvement of the C-
terminal region in the mechanism of prion formation, but also
that there is interplay between the N-terminal and C-terminal
regions of the protein. The locations of these various mutations
are scattered across the protein structure (see Fig. 5). Therefore,
it is hard to predict simply from inspection of the wild-type
structure the effect the mutations have on the conformation and
folding of the protein. Further biophysical studies to character-
ize the structural and folding properties of these mutants may
yield important insight into the molecular mechanism of prion
induction and propagation.
3.2. Chaperones
Molecular chaperones play an important role in the cell to
ensure that proteins fold correctly to their native functional
conformation [74,75]. Many chaperones are also classed as heat
shock proteins (Hsps), as their expression is up-regulated under
conditions of cellular stress, when proteins may be particularly
likely to unfold and aggregate. Genetic studies have identified a
number of chaperones that modulate the behaviour of yeast
prions [76]. In particular, the three best characterized S.
cerevisiae prions, Sup35, Ure2 and Rnq1, all require normal
expression levels of the chaperone Hsp104 in order to be
propagated efficiently [13,77,78]. In the case of Sup35,
inhibition of the ATPase activity of Hsp104 similarly interferes
with prion propagation [79–81] and overexpression of Hsp104
also results in curing of the prion phenotype [77]. To account for
these observations, it is proposed that Hsp104 is required to
produce new seeds from existing prion aggregates; while
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aggregates [82–86]. This is consistent with the cellular role of
Hsp104 in disassembly of existing protein aggregates, in
cooperation with the Hsp70 chaperone system [87,88].
Hsp70 and its co-chaperone Hsp40 have also been
implicated in the propagation of yeast prions. Overexpression
of Ydj1–Hsp40 or Ssa1–Hsp70 (but not Ssa2–Hsp70) is able to
cure [URE3] [78,89]. In addition, a missense mutation within
the Ssa2–Hsp70 peptide-binding domain alters [URE3] stability
[90]. Detailed genetic analysis has identified mutations in both
the ATPase and peptide-binding domains of Ssa1–Hsp70 that
alter stability of the [PSI+] prion [91,92]. However, the clear
predominance of Hsp70 ATPase domain mutations that alter
[PSI+] propagation suggests that modifying the rate of ATP
hydrolysis is a major factor in the ability of Hsp70 to alter prion
propagation [92] (H.M. Loovers and G.W.J., unpublished data).
Interplay between Hsp104 and Hsp70 in maintenance of [PSI+]
is also observed [93]. Sis1–Hsp40 (but not Ydj1) is required for
propagation of [RNQ+], although immunoprecipitation experi-
ments indicate that both proteins interact with Rnq1 [94], and
overexpression of Ydj1 is able to cure [RNQ+] [95].
The complexity of the chaperone–prion relationship is
highlighted by the varying effects on prion propagation that
have been observed. In addition to the apparent differences in
effect on [URE3] of different members of the Hsp70–Ssa
family, varying effects of Ssa1 upon propagation of [PSI+]
variants has also been reported [96]. Further, while over-
expression of Hsp104 causes curing of [PSI+] [77], stability of
[URE3] appears to be unaffected [78], even though propagation
of both prions is dependent on the presence of normal levels of
Hsp104. These varying effects most likely reflect differences in
amyloid structure of different prions or prion strains and/or
subtle differences in substrate preference for related chaperone
machineries.
Involvement of the Hsp70 chaperone system in yeast prion
maintenance and curing is consistent with the finding that
overexpression of Hsp70 suppresses polyglutamine-associated
pathogenicity and reduces the formation of amyloid fibrils
[97,98], and suggests that the Hsp70 family may have a
universal role in suppressing the formation of pathogenic
aggregates, including prions. However, to date, direct demon-
stration of an interaction between Hsp70 and yeast prions by in
vitro biochemical analysis has not yet been reported.
4. Folding and stability of Ure2
4.1. Relationship between folding and amyloid formation
Various models have been proposed to describe the
mechanism of amyloid or prion formation [99–101]. In general,
amyloidogenic proteins show a sigmoidal time-course of fibril
formation and the lag time can be reduced or circumvented by
the addition of preformed fibril ‘seeds’, indicating that the
process involves a nucleation step analogous to growth of
protein crystals. Another commonly described feature is that the
length of the lag time decreases with increasing protein
concentration in an approximately exponential relationship. Infact, for Ure2 [36,102] and also for Sup35 [103], the
relationship between increasing protein concentration and
decreasing lag time is linear. This may reflect a variation in
mechanism, the oligomeric nature of the native state, or simply
the choice of reaction conditions [36,101,103]. Nevertheless, a
common feature of the various models is the involvement of
partially-folded (or misfolded) intermediate states, implying
that the mechanism of amyloid or prion formation is related to
the pathway by which the protein folds (or misfolds). Therefore,
characterization of the folding behaviour of the prion proteins is
an important step in elucidating the mechanism of prion
formation. This is easier said than done, as the prion proteins, by
definition, are prone to aggregate, which tends to interfere with
the standard approaches used in protein folding studies.
Nevertheless, in comparison with the other known prion
proteins, the Ure2 protein represents a relatively tractable
model and its folding behaviour has already been characterized
in some detail.
4.2. Role of the N-terminal prion domain in Ure2 structure and
folding
Genetic studies have demonstrated the involvement of the N-
terminal prion domain in [URE3] prion induction and
propagation [31], whereas the nitrogen regulatory function is
conveyed by the GST-like C-terminal region [29]. Subsequent
biophysical analysis of the purified Ure2 protein has shown that
the structural properties of the N-terminal and C-terminal
regions are also distinct. The N-terminal domain is extremely
sensitive to protease digestion [26–28,104] and progressive
deletion of the N-terminal domain has no effect on the
dimerisation, stability or folding kinetics of the protein in
vitro [27,33,35,36,105] (see Fig. 6). This implies that the N-
terminal prion domain is in a relatively unstructured, flexible
conformation and does not interact significantly with the C-
terminal globular domain in the native state. Ayeast two-hybrid
analysis study detected interaction between N- and C-terminal
fragments of Ure2 [106] and the presence of the N-terminal
domain improves the efficiency of the nitrogen catabolite
repression activity of the C-terminal domain [31,69], suggesting
that these domains are able to interact in vivo. However, a more
recent study failed to detect an interaction by yeast two-hybrid
analysis [107]. It has also been confirmed by NMR spectros-
copy that the N-terminal domain is unstructured in vitro [107].
Thus the support for direct interaction between the N-terminal
and C-terminal domains of Ure2 seems to be ephemeral, but it
remains likely that indirect interaction may occur via a binding
partner such as Gln3 and/or a chaperone.
A common theme in the conversion from native to prion
forms for both mammalian and fungal prions appears to be the
transition from an unstructured to a β-rich form, which is
analogous to the conformational changes observed for natively-
unfolded amyloidogenic proteins such as the Parkinson's
Disease-related protein α-synuclein and the Alzheimer's
Disease-related protein tau [108]. The ability to form fibrils of
a variety of chimeras containing the unstructured Ure2 prion
domain attached to unrelated globular protein domains
Fig. 6. Effect of deletion of the N-terminal prion domain on Ure2 stability and folding kinetics. The experimental conditions were 50 mM Tris–HCl buffer pH 8.4, 0.2
M NaCl. (A) Guanidinium chloride induced denaturation of WT Ure2 (●) and N-terminal deletion mutants (see Fig. 2) 15Ure2 (○), 42Ure2 (□) and 105Ure2 (⋄).
Data taken from [36] and (Y.J. et al. and S.P., in preparation). (B) Chevron plot showing the dependence of the unfolding and refolding rate constants for WT Ure2 (▾)
and N-terminal deletion mutants 90Ure2 (○) and Δ15–42Ure2 (●). Second-order rate constants for the fast phase of refolding (□). Data taken from [35].
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principal driving force in Ure2 fibril formation.
4.3. Comparison of different denaturation methods
Ure2 is a remarkably stable protein and derives a significant
amount of this stability from its existence as a dimer [36]. The
majority of folding studies that have been carried out have used
the chemical denaturant and salt, guanidinium chloride
(GdmCl). This is because milder (and arguably more physio-
logical) denaturants such as acid, alkali, urea (up to 8 M) [27] or
pressure (up to 600 Mpa) [105,111] are each insufficient to
unfold the protein; and temperature denaturation is irreversible
[27]. In order to guarantee that the thermodynamic parameters
obtained from denaturation experiments are meaningful and can
be interpreted, it is important to demonstrate reversibility of
unfolding; typically this is done by gradually unfolding the
protein and comparing the results obtained when the experiment
is done in reverse i.e. by first completely unfolding the protein
and then gradually refolding it. In the case of Ure2, to obtain
ideal results in this two-way experiment requires a careful
balance of pH, temperature, protein concentration and choice of
buffer [27]. The conditions found to be ‘ideal’ for folding
experiments (Tris–HCl buffer pH 8.4, 0.2 M NaCl, 25 °C and 1
μM protein concentration) unsurprisingly resemble the condi-
tions adopted for Ure2 purification in a variety of labs
[26,27,32,109], and coincide with maximal stabilization of the
native state of Ure2 with respect to partially-folded intermedi-
ates [36]. Nevertheless, under these conditions, the folding
kinetics of Ure2 is extremely complex and a variety of folding
intermediates are transiently populated during unfolding or
refolding [27,35,36].
Although the N-terminal domain does not contribute to the
stability of the Ure2 protein in vitro [27], or affect the pathway
of folding [35], the presence of the prion domain has a marked
effect on the solubility of the protein [27]. Interestingly,
conditions where Ure2 is relatively destabilized, such as at
lower pH, or in phosphate rather than Tris buffer, also coincidewith conditions where the protein more readily forms fibrils,
implying that the mechanism of fibril formation may involve
partial unfolding [33,36]. However, destabilizing conditions are
also associated with an increased degree of non-specific (i.e.
PrD-independent) aggregation, which can compete with fibril
formation and complicate the analysis [36]. Another interesting
observation is that relatively small deletions in the N-terminal
domain, such as deletion of residues 1–15 or 15–42 (see Figs. 2
and 4) have a marked effect on both the solubility of the protein
[27] and the lag time of fibril formation [34], implying that these
regions contribute to nucleation of amyloid-like structure. The
lower propensity of mutants such asΔ15–42Ure2 (see Fig. 2) to
undergo non-specific aggregation and to form amyloid makes
them particularly useful for use in rigorous folding studies
[27,35,36,105,112].
4.4. Mechanism of folding
The Ure2 protein readily populates an intermediate under
equilibrium conditions at GdmCl concentrations of 2–3 M; the
protein concentration dependence of the further unfolding of
this intermediate demonstrates that dissociation is coupled to
unfolding and hence the intermediate is dimeric rather than
monomeric (see Fig. 7A). No other intermediates are readily
detected under equilibrium conditions, which reflects the
relative stability of the native dimer and dimeric intermediate
compared to their monomeric counterparts [36]. The native state
is destabilized with respect to the dimeric intermediate at pH
lower than 8.5 (see Fig. 7B), or in phosphate compared to Tris
buffer (see Fig. 7B, inset), and so the intermediate is more easily
observed under these conditions.
Kinetic folding studies using stopped-flowmethods allow the
detection of further intermediates. When Ure2 is unfolded in
GdmCl and then refolded by rapid dilution, three folding phases
can be distinguished, implying multiple processes in refolding,
such as population of folding intermediates [35]. The fastest
phase is attributed to population of a monomeric intermediate,
on the basis that this intermediate can be trapped by aggregation
Fig. 7. Protein concentration and pH dependence of Ure2 denaturation induced by guanidinium hydrochloride. The results indicate that a dimeric intermediate is
populated during denaturation; and the native state is progressively destabilized when the pH is decreased from 8.5 to 7.0. Experimental conditions were 50 mMNa–K
phosphate buffer, 0.15 M NaCl and 1 μM Ure2, unless otherwise stated. Data taken from [36]. (A) Ure2 concentration 0.2 μM (●), 1 μM (□), 5 μM (■) and 20 μM
(○) at pH 8.5. (B) pH 7.0 (○), pH 7.5 (■), pH 8.0 (□) and pH 8.5 (●). Inset: phosphate (○) and Tris–HCl (●) buffer at pH 7.0.
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disfavour dimerisation and correct folding [27,35]. The next
observable folding phase shows protein concentration depen-
dence consistent with a second order reaction i.e. this phase
corresponds to formation of a dimeric intermediate [35]. The
final observable folding phase is protein concentration indepen-
dent. Unusually, it is possible to detect a lag for this folding
phase; the length of the lag decreases with increasing protein
concentration. This then indicates that final folding to the native
state occurs only after formation of the dimeric folding
intermediate and that formation of this intermediate is an
obligatory step on the folding pathway [35]. In fact, structural
changes continue to occur even after no further spectroscopic
changes are detected and the native state of Ure2 is regained only
very slowly; this slow structural rearrangement is attributed to
the unusual cis conformation of Pro166 in the native state,
requiring isomerisation from the dominant trans form [35]. The
inability to distinguish the true native state from the spectro-
scopically similar pseudo-native state is a common problem in
folding studies. These two states of Ure2 can be distinguished by
their markedly different stabilities and unfolding rates, as
detected by a ‘double-jump’ experiment [35]. Another method
for distinguishing such states is by activity assay, and so the
recent development of an in vitro assay for Ure2 enzyme activity
[64] provides a useful tool for further folding studies.
A further folding intermediate can be detected during
unfolding experiments and has been identified as a native-like
monomer [36]. This intermediate is only populated under extreme
conditions of high denaturant concentration, reflecting the
extreme stability of the Ure2 dimer, even at micromolar protein
concentrations [35,36]. Tethering the two halves of the Ure2
dimer by the introduction of an artificial disulphide bond prevents
fibril formation under conditions where the wild-type protein
forms fibrils, suggesting that dimer dissociation is necessary for
Ure2 fibril formation [113], although the effect of the disulphide
bond on other aspects of the stability and folding of the protein
could also play a role. The relationship between population of a
partially-folded intermediate and conditions which favour fibril
formation also points towards partial unfolding in the process ofamyloid formation [33,36]. Likewise, the ability of mutations in
the C-domain to influence prion induction [72,73] implies that the
mechanisms of folding and fibril formation are intertwined.
However, which, if any, of the intermediates that have been
described thus far are involved in this process remains an open
question. Further, the propensity of these intermediates to
undergo non-specific aggregation [27,33,35,36,112] presents a
significant challenge to their direct characterization.
5. Conclusions
The Ure2 protein shows a number of remarkable features,
not least its ability to undergo a heritable conformational change
to an aggregated prion state, while still retaining the enzymatic
activity of its native form. The presence of natively unfolded
structure in the Ure2 N-terminal prion domain is a feature that is
common to the prion proteins identified to date and may be an
essential characteristic of prions. The ability of C-terminal
deletions or mutations to influence prion induction suggests that
there is some involvement of the C-terminal domain in the
mechanism of Ure2 prion formation; but whether this is due to a
direct effect (such as on the thermodynamics or kinetics of
folding or dimer dissociation) or an indirect effect (such as on
the recruitment and binding of chaperones or other cofactors)
remains to be determined. The convenience of the yeast system
to screen for factors that influence prion stability in vivo,
combined with the suitability of the Ure2 protein for detailed
folding analysis in vitro, makes this a promising model to shed
light on the molecular mechanism of prion propagation.Acknowledgements
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